Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Brain inflammatory thrombogenic vasculopathy related with SARS-CoV-2 infection
Journal Information
Vol. 35. Issue 9.
Pages 701-703 (November - December 2020)
Share
Share
Download PDF
More article options
Vol. 35. Issue 9.
Pages 701-703 (November - December 2020)
Letter to the Editor
Open Access
Brain inflammatory thrombogenic vasculopathy related with SARS-CoV-2 infection
Vasculopatía trombogénica inflamatoria del cerebro relacionada con la infección del SARS-CoV-2
Visits
1141
J. Porta-Etessama,
Corresponding author
jporta@yahoo.com

Corresponding author.
, M. Yusb, N. González Garcíaa, A. Valcarcelc, J. Barrado-Cuchilloc, J. Pérez-Somarribac
a Neurology Department, Hospital Clínico San Carlos, Madrid, Spain
b Radiology Department, Hospital Clínico San Carlos, Madrid, Spain
c Internal Medicine Department, Hospital Clínico San Carlos, Madrid, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
Dear Editor:

The SARS-CoV-2 virus was first identified in December 2019 in the city of Wuhan, China. This novel betacoronaviridae has been related with several neurological symptoms and complication, as anosmia, headache, seizure and stroke.1 The relationship with stroke could be explained by coagulopathy and endothelial dysfunction and there is a theoretical risk for large-vessel stroke.2 We report a 70-years-old man with subacute encephalopathy due to a multiple brain acute vascular lesions presumably related with CoviD-19 vasculopathy.

We present a 70-year-old man with a diagnosis of Bence-Jones light chain disease that was admitted to hospital at the end of March complained about fever and cough. The temperature was 38°C (100.4°F). Neurological examination at admission was unremarkable. A chest X-ray was performed, showing new bilateral infiltrates and PCR for SARS-CoV-2 was positive. The patient was started with hydroxychloroquine and support oxygen therapy for 7 days. Ten days later, the patient experienced began with an episode of subacute disorientation and conduct disorder, without any neurological focal symptomatology. We perform a An unenhanced cranial CT that showed showing multiple low attenuate hypodense brain and cerebellar lesions, and a brain MRI with angiographic sequence acquired a week later confirmed confirms multiple supra and infratentorial subacute ischemic lesions, without large and medium vessel occlusion or stenosis (Fig. 1a and b). An extended study that included transthoracic and transesophageal echocardiography, antiphospholipid antibodies, supra aortic arteries study was normal. Therefore, it was decided to start anticoagulant treatment, with a good evolution until the resolution of the clinical situation. Discussion

Figure 1.

(a) CT image (A) from PET/CT scan evaluation for the light-chain disease showing no abnormality ten days before the onset of fever. Chest RX (B) showing bilateral lung infiltrates. Different slices from head CT (C) obtained after the patient developed neurological symptoms demonstrating several low attenuating lesions (arrows), both cortical and white matter locations. (b) Different sequences from a MRI study obtained a week after the start of the neurological symptoms. FLAIR slices (A), gradient-echo (B), postgadolinium injection 3D FSPGR T1-weighted slices (C), ADC map (D) and diffusion-weighted slices, showing several subacute small infarcts (arrows), with high signal in both T2 and DWI images, contrast enhancement, and decreased ADC values in some of them.

(0.62MB).

We present a patient with Bence-Jones light chain disease and CoviD19 that developed an encephalopathy due to multivascular acute lesions. We hypothesize that the lesions could be related with a SARS-CoV-2 induce rain vasculopathy. Is well known, that the ACE2 receptor allows the virus that causes COVID-19 to infect and destroy our cells.3 Brain capillary express ACE2 receptor.4 This could induce an inflammatory thrombogenic vasculopathy. This catastrophic microvascular injury syndrome mediated by activation of complement pathways and the associated procoagulant state could explain this findings.5 The microvascular injury could be also related with the high incidence of Post-intensive Care Syndrome in CoviD-19.6 We propose that every patient with encephalopathy, acute neurological non focal symptoms or post-intensive-care syndrome should be studied to rule out a microvascular damage.

References
[1]
Y. Li, M. Li, M. Whang, et al.
Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study [published online ahead of print, 2020 Jul 2].
Stroke Vasc Neurol. 2020;svn-2020-000431., (2020),
[2]
T.J. Oxley, J. Mocco, S. Majidi, et al.
Large-vessel stroke as a presenting feature of covid-19 in the young.
N Engl J Med, 382 (2020), pp. e60
[3]
A. Hasan, B.A. Paray, A. Hussain, et al.
A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin [published online ahead of print, 2020 Apr 22].
J Biomol Struct Dyn, (2020), pp. 1-9
[4]
M. Mogi, M. Horiuchi.
Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
Geriatr Gerontol Int, 13 (2013), pp. 13-18
[5]
C. Magro, J.J. Mulvey, D. Berlin, et al.
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases [published online ahead of print, 2020 Apr 15].
[6]
Conklin J, Frosch MP, Mukerji S, et al. Cerebral Microvascular Injury in Severe COVID-19. Preprint medRxiv. 2020; 2020.07.21.20159376. Published 2020 Jul 24. doi:10.1101/2020.07.21.20159376.
Copyright © 2020. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.nrleng.2018.05.014
No mostrar más